Name | Title | Contact Details |
---|---|---|
Trevor Woodage |
Assistant General Counsel, Intellectual Property | Profile |
Shane Bohnen |
Associate General Counsel | Profile |
Shane Bohnen |
Senior Vice President and General Counsel | Profile |
Brenda Furlow |
General Counsel | Profile |
Brenda Furlow |
Executive Vice President, General Counsel and Chief Sustainability and Compliance Officer | Profile |
MeMed is a host response, med-tech & bioconvergence company, offering innovative diagnostic host response tests that address complex clinical dilemmas & improve patient outcomes.
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization.
Synthorx Inc. is a biotechnology company using synthetic biology to discover and develop novel protein therapeutics. Synthorx`s expanded genetic alphabet platform has the unique ability to drive the site-specific incorporation of multiple synthetic amino acids into proteins thereby tuning receptor specificity important for improving efficacy and safety. In addition, their engineered organisms provide the ability to manufacture these improved proteins, called Synthorins, with the required fidelity and yield. The unique Synthorx platform expands the chemical and structural repertoire of protein therapeutics and uncovers new ways to modulate pharmacological properties of biologics, not possible with other technologies. The company was founded based on important discoveries in Dr. Floyd Romesberg`s lab at The Scripps Research Institute in conjunction with Avalon Ventures, which housed Synthorx in its incubator, COI Pharmaceuticals, Inc. The company is headquartered in La Jolla, Calif.
Myrexis, Inc. is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Viridian Therapeutics focuses in advancing new treatments for patients with diseases that are underserved by today`s therapies.